New Cystic Fibrosis Clinical Trial to be Launched by Kamada Ltd. this Summer

Israel-based Kamada Ltd., a drug development company currently developing plasma-derived protein therapeutics that are chiefly targeting orphan diseases, indicated recently in a press release that their lead drug candidate Alpha-1 Antitrypsin (AAT), which is currently in trials for treatment of Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema), will also be tested in a new round of clinical trials for cystic fibrosis this summer. Continue reading New Cystic Fibrosis Clinical Trial to be Launched by Kamada Ltd. this Summer

N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

BOULDER, Colo., March 12, 2014 /PRNewswire/ — N30 Pharmaceuticals, Inc. (“N30 Pharma”) announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF). Continue reading N30 Pharmaceuticals Initiates Phase 1 Clinical Trial for Novel Cystic Fibrosis Therapy

CF and MRSA Clinical Trial by Savara Pharmaceutical

CLINICAL TRIAL
Are you a CF patient with persistent MRSA lung infection? If so, you may be interested in a Phase 2 clinical trial designed to evaluate the safety and efficacy of AeroVanc (vancomycin hydrochloride inhalation powder), the first inhaled antibiotic Continue reading CF and MRSA Clinical Trial by Savara Pharmaceutical

New Analysis Indicates Cystic Fibrosis Transmembrane Conductance Regulator Modulators Will Lead To Significant Treatment Improvements

The vast majority of Cystic Fibrosis treatments currently approved by the Food and Drug Administration focus on managing and curtailing symptoms of the disease rather than treating its underlying causes. However, a new pharma report from GBI Research Continue reading New Analysis Indicates Cystic Fibrosis Transmembrane Conductance Regulator Modulators Will Lead To Significant Treatment Improvements

MRSA trial now recruiting patients

A new phase II trial is currently recruiting cystic fibrosis (CF) patients with persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection to determine the effectiveness, safety, and pharmacokinetics of a new investigational inhalable powder formulation of vancomycin called Continue reading MRSA trial now recruiting patients

Clinical Trials: A Vital Part of Cystic Fibrosis Treatment Advancements

Clinical trials are vital part of advancing treatments for CF patients. Fundraising is the genesis for new treatments because it allows researchers to create new treatments, but clinical trials are the bridge from a breakthrough in the lab to a new medicine actually being available on the open Continue reading Clinical Trials: A Vital Part of Cystic Fibrosis Treatment Advancements